US Gov't Plans To Control COVID Vaccine Distribution At Least Through 2022; Already Authorized Products Have Booster Advantage
Due to need to plan for potential vaccine boosters now, administration is focusing on contracting with the companies whose shots are already being given in the US, David Kessler tells the Senate health committee. Data on whether it is ok to ‘mix and match’ vaccine types with boosters should be available in a few months.
You may also be interested in...
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
COVID-19 Vaccines: Declining Antibody Levels, Breakthrough Infections Could Spur Booster Recommendations
Although data to support use of booster doses currently are lacking, members of the US CDC's Advisory Committee on Immunization Practices suggest potential triggers for recommending revaccination after the primary series.
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.